Table 1 Patients’ characteristics and treatment adherence according to the care centers. N = 294

Gender

Male

153

52

51

62

34

49

68

48

Female

141

48

31

38

36

51

74

52

Age (tercile)

t1 (until 59y)

88

30

24

29

20

29

44

31

t2 (60y to 72y)

156

53

40

49

37

53

79

56

t3 (73y and more)

50

17

18

22

13

19

19

13

Comorbidity

None

117

40

36

44

26

37

55

39

At least 1

177

60

46

56

44

63

87

61

Performance status (0 / 1–4)

Normal

234

80

67

82

45

64

122

86

Degraded

60

20

15

18

25

36

20

14

Social deprivation index

Highly fav.

63

21

18

22

10

14

35

25

Fav.

43

15

14

17

13

19

16

11

Intermediate

68

23

22

27

18

26

28

20

Dep.

74

25

13

16

19

27

42

30

Highly dep.

46

16

15

18

10

14

21

15

Nearest care center

UH

119

40

8

10

0

0

111

78

Other

175

60

74

90

70

100

31

22

Distance (km) to the care center

Mean (SD)

38

(59)

23

(30)

28

(29)

51

(76)

Med [q1-q3]

20

[7; 47]

12

[4;30]

24

[7; 39]

23

[10; 68]

Distance (km) to the teaching hospital

Mean (SD)

87

(74)

123

(62)

119

(42)

51

(76)

Med [q1-q3]

75

[22; 137]

128

[69;176]

113

[81;155]

23

[10; 71]

Stage

I/II

123

42

44

54

26

37

53

37

III/IV

171

58

38

46

44

63

89

63

LDH: lactate dehygrogenase

Normal

163

55

50

61

49

70

64

45

Elevated

131

45

32

39

21

30

78

55

B symptoms

Absence

255

87

75

91

55

79

125

88

Presence

39

13

7

9

15

21

17

12

Hospitalization for toxicity

None

240

82

71

87

44

63

125

88

At least 1 day

54

18

11

13

26

37

17

12

Relative dose intensity (RDI)

Mean (SD)

0.97

(0.10)

0.95

(0.11)

0.95

(0.12)

0.98

(0.08)

Med [q1-q3]

1

[1; 1]

1

[0.9; 1]

1

[0.9; 1]

1

[1; 1]

Relative Dose Intensity (RDI)

RDI = 100 %

229

78

58

71

50

71

121

85

RDI < 100 %

65

22

24

29

20

29

21

15